Antifungal clinical trials and guidelines: what we know and do not know

Area of Science:

• Medical Mycology
• Infectious Diseases
• Clinical Trials

Background:

• Treatment guidelines for invasive fungal infections (e.g., cryptococcosis, candidiasis, aspergillosis) have been established over three decades.
• Current guidelines rely on widely recognized clinical trials comparing antifungal agents.
• Significant challenges persist in diagnosing and treating emerging invasive fungal infections.

Purpose of the Study:

• To review major advances in the management of invasive mycoses.
• To highlight significant challenges that remain in antifungal therapy and diagnostics.
• To emphasize the need for improved diagnostic tools and therapeutic agents.

Main Methods:

• Review of clinical trials and established treatment guidelines for invasive fungal infections.
• Analysis of current antifungal armamentarium and diagnostic capabilities in medical mycology.
• Discussion of unmet needs in antifungal drug development and diagnostic technology.

Main Results:

• Antifungal agents have improved since amphotericin B, but more effective and less toxic options are needed.
• Mycology diagnostics lag behind other fields, with a scarcity of rapid, sensitive, specific, and point-of-care tests.
• Early diagnostic signals could enable targeted and specific antifungal interventions for at-risk patients.

Conclusions:

• Continued research is essential for developing novel antifungal therapies with improved efficacy and safety profiles.
• Advancements in rapid and accurate diagnostics are critical for timely and targeted treatment of invasive fungal infections.
• Addressing these challenges will significantly enhance patient outcomes in managing invasive mycoses.